VCYT Veracyte Diagnostics: Nilai Akuntansi saben Saham

This chart reflects that the asset value of Veracyte, Inc. (VCYT), which specializes in high-precision oncology diagnostics, currently stands at 17.13. Mark Staple is effectively integrating innovative screenings into global practice, supported by rigorous operational control. The business is protected by patents for AI solutions and complex FDA certification, while an impeccable image as a scientific pioneer ensures full confidence from the professional medical community.

Veracyte Inc (VCYT) - Nilai Akuntansi saben Saham saka 04.07.2022 nganti 27.10.2026

Ringkesan rincian data analitis veracyte.com (VCYT)

- rega lan prakiraan konsensus rega:

Kutipan saham Veracyte Corp|VCYT - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar Veracyte, Inc.|VCYT - Total Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Veracyte|VCYT - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku veracyte.com|VCYT - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Veracyte, Inc.|VCYT - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Veracyte|VCYT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Veracyte, Inc.

Analisis kabeh metrik perusahaan:Veracyte Corp, VCYT

Selecting stocks with a high margin of safety begins with an assessment of equity. This indicator is calculated as the difference between all company assets and liabilities, divided by the number of shares. For Veracyte, Inc. (VCYT), this metric reflects the integration efficiency of European laboratories and M&A transactions. Growth in net asset value confirms successful business expansion. By analyzing the book value per common share trend, an investor can see the company's actual tangible asset base.

Analisis pesaing Veracyte, Inc.